ImmunoGen, Inc. - IMGN - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

ImmunoGen, Inc. - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
IMGN	Nasdaq	8731	http://www.immunogen.com	15.96 0.00
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for ImmunoGen, Inc. Why ImmunoGen Is a Buy Right Now? - Jun 15th, 2013 3:16 pm A Trio of Cancer Immunotherapy Innovators - Jun 15th, 2013 10:17 am ImmunoGen's Management Presents at Goldman Sachs 34th Annual Global Healthcare Conference (Transcript) - Jun 13th, 2013 3:35 pm 5 of Last Week's Biggest Losers - Jun 9th, 2013 5:15 am IMMUNOGEN INC Files SEC form 8-K, Other Events - Jun 6th, 2013 10:32 pm First Clinical Data Presented with IMGN853, ImmunoGen, Inc.’s Potential New Therapy for Ovarian and Other Cancers - Jun 3rd, 2013 4:30 am Tackling Cancer: Your Best Investing Ideas - Jun 2nd, 2013 12:05 pm Nasdaq stocks posting largest percentage decreases - May 31st, 2013 4:04 pm Why Immunomedics Shares Soared - May 30th, 2013 2:27 pm ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences - May 30th, 2013 9:30 am Angelina Jolie's Selfless Act Heightens Breast Cancer Awareness - May 15th, 2013 4:40 pm Companies Invest in Antibodies That Fight Tumors - May 13th, 2013 2:54 pm ImmunoGen's Management Presents at Credit Suisse Antibody Day Conference (Transcript) - May 11th, 2013 8:58 pm IMMUNOGEN INC Financials - May 10th, 2013 11:04 am ImmunoGen's Symbiotic Relationships Thru TAP Will Beef Up Its Stock Price - May 9th, 2013 2:18 pm IMMUNOGEN INC Files SEC form 10-Q, Quarterly Report - May 6th, 2013 1:20 am Dr. Jason Kantor, Research Analyst at Credit Suisse Group, Interviews with The Wall Street Transcript: High Success Rates and Significant M&A in the Antibody Space - May 3rd, 2013 9:17 am ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conference - May 3rd, 2013 4:30 am A Favorable Regulatory Environment for Biotechnology and Pharmaceutical Companies: Senior Analyst Brian Skorney Discusses the Acceleration of FDA Approvals with The Wall Street Transcript - Apr 29th, 2013 9:22 am ImmunoGen Narrows Loss - Apr 29th, 2013 7:05 am View All Current Headlines >>